GT Biopharma Reports Second Quarter 2026 Financial Results
GT Biopharma reported Q2 financial results and clinical updates, confirming that Phase 1 trials for GTB-3650 and GTB-5550 remain ongoing with data updates anticipated in the second half of 2026. The company posted a net loss of $4.5 million for the quarter, compared to a net loss of $30.2 million in the prior year, though operating losses widened to $4.5 million from $1.5 million due to increased R&D and SG&A expenses.
Key figures
- Net loss
- 4500000
- Cash runway
- Q4 2026
- Rd expenses
- 1100000
- Cash balance
- 5100000
- Sga expenses
- 3400000
- Operating loss
- 4500000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.